JPWO2020092694A5 - - Google Patents

Download PDF

Info

Publication number: JPWO2020092694A5
Authority: JP; Japan
Prior art keywords: cells; hematopoietic stem; optionally substituted; patient; hematopoietic
Prior art date: 2022-11-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2021522019A

Other languages

English (en)

Japanese (ja)

Other versions

JP2022505615A (ja

Publication date

2022-11-09

2019-10-31 Application filed filed Critical

2019-10-31 Priority claimed from PCT/US2019/059039 external-priority patent/WO2020092694A2/en

2022-01-14 Publication of JP2022505615A publication Critical patent/JP2022505615A/ja

2022-11-09 Publication of JPWO2020092694A5 publication Critical patent/JPWO2020092694A5/ja

Status Pending legal-status Critical Current

Links

-1 nicotine amides Chemical class 0.000 claims description 974
210000003958 Hematopoietic Stem Cells Anatomy 0.000 claims description 598
230000003750 conditioning Effects 0.000 claims description 257
210000004027 cells Anatomy 0.000 claims description 252
COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 134
229960002092 busulfan Drugs 0.000 claims description 134
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 128
150000001875 compounds Chemical group 0.000 claims description 109
210000000130 stem cell Anatomy 0.000 claims description 101
238000002560 therapeutic procedure Methods 0.000 claims description 99
229910052739 hydrogen Inorganic materials 0.000 claims description 88
239000001257 hydrogen Substances 0.000 claims description 86
102000003984 Aryl hydrocarbon receptors Human genes 0.000 claims description 83
108090000448 Aryl hydrocarbon receptors Proteins 0.000 claims description 83
201000010099 disease Diseases 0.000 claims description 80
238000002347 injection Methods 0.000 claims description 78
239000007924 injection Substances 0.000 claims description 78
238000002054 transplantation Methods 0.000 claims description 75
108060001251 CD34 Proteins 0.000 claims description 74
102100016492 CD34 Human genes 0.000 claims description 74
125000000217 alkyl group Chemical group 0.000 claims description 73
230000001494 anti-thymocyte Effects 0.000 claims description 70
125000001072 heteroaryl group Chemical group 0.000 claims description 69
230000001363 autoimmune Effects 0.000 claims description 68
238000011134 hematopoietic stem cell transplantation Methods 0.000 claims description 67
230000003394 haemopoietic Effects 0.000 claims description 66
229960004397 Cyclophosphamide Drugs 0.000 claims description 64
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 64
239000002464 receptor antagonist Substances 0.000 claims description 61
125000000592 heterocycloalkyl group Chemical group 0.000 claims description 60
241000283973 Oryctolagus cuniculus Species 0.000 claims description 59
206010033661 Pancytopenia Diseases 0.000 claims description 58
UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 56
125000003107 substituted aryl group Chemical group 0.000 claims description 56
239000003795 chemical substances by application Substances 0.000 claims description 54
230000001143 conditioned Effects 0.000 claims description 53
239000000203 mixture Substances 0.000 claims description 49
OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 claims description 45
210000004700 Fetal Blood Anatomy 0.000 claims description 44
125000004404 heteroalkyl group Chemical group 0.000 claims description 44
239000011780 sodium chloride Substances 0.000 claims description 42
150000003839 salts Chemical class 0.000 claims description 41
229960000390 fludarabine Drugs 0.000 claims description 40
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 40
125000000547 substituted alkyl group Chemical group 0.000 claims description 39
239000012453 solvate Substances 0.000 claims description 36
229940121384 CXC chemokine receptor type 4 (CXCR4) antagonists Drugs 0.000 claims description 31
125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 30
206010022000 Influenza Diseases 0.000 claims description 29
150000002431 hydrogen Chemical group 0.000 claims description 29
210000003719 B-Lymphocytes Anatomy 0.000 claims description 28
210000001772 Blood Platelets Anatomy 0.000 claims description 27
108090001123 antibodies Proteins 0.000 claims description 27
102000004965 antibodies Human genes 0.000 claims description 27
239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 claims description 23
229940107955 Thymoglobulin Drugs 0.000 claims description 21
108010056900 thymoglobulin Proteins 0.000 claims description 21
210000003743 Erythrocytes Anatomy 0.000 claims description 19
239000002168 alkylating agent Substances 0.000 claims description 19
230000035755 proliferation Effects 0.000 claims description 19
230000000069 prophylaxis Effects 0.000 claims description 19
230000002829 reduced Effects 0.000 claims description 19
125000000753 cycloalkyl group Chemical group 0.000 claims description 18
210000001744 T-Lymphocytes Anatomy 0.000 claims description 16
210000001519 tissues Anatomy 0.000 claims description 16
RTGDFNSFWBGLEC-SYZQJQIISA-N 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate Chemical group COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 15
208000008466 Metabolic Disease Diseases 0.000 claims description 15
201000011510 cancer Diseases 0.000 claims description 15
229960004866 mycophenolate mofetil Drugs 0.000 claims description 15
230000003405 preventing Effects 0.000 claims description 15
108010036949 Cyclosporine Proteins 0.000 claims description 14
210000000822 Killer Cells, Natural Anatomy 0.000 claims description 13
210000000440 Neutrophils Anatomy 0.000 claims description 13
PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 12
229960001265 ciclosporin Drugs 0.000 claims description 12
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 11
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 11
210000003714 Granulocytes Anatomy 0.000 claims description 11
210000002381 Plasma Anatomy 0.000 claims description 11
239000000556 agonist Substances 0.000 claims description 11
102100004948 ABCD1 Human genes 0.000 claims description 10
210000004443 Dendritic Cells Anatomy 0.000 claims description 10
208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims description 10
201000011451 Krabbe disease Diseases 0.000 claims description 10
210000002540 Macrophages Anatomy 0.000 claims description 10
108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims description 10
201000011452 adrenoleukodystrophy Diseases 0.000 claims description 10
241000283073 Equus caballus Species 0.000 claims description 9
230000002490 cerebral Effects 0.000 claims description 9
206010003816 Autoimmune disease Diseases 0.000 claims description 8
210000003979 Eosinophils Anatomy 0.000 claims description 8
239000003018 immunosuppressive agent Substances 0.000 claims description 8
210000000612 Antigen-Presenting Cells Anatomy 0.000 claims description 7
MCWXGJITAZMZEV-UHFFFAOYSA-N Dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 claims description 7
210000000138 Mast Cells Anatomy 0.000 claims description 7
210000000274 Microglia Anatomy 0.000 claims description 7
108010001645 Rituximab Proteins 0.000 claims description 7
230000000735 allogeneic Effects 0.000 claims description 7
210000003008 brain-resident macrophage Anatomy 0.000 claims description 7
230000011132 hemopoiesis Effects 0.000 claims description 7
201000011442 metachromatic leukodystrophy Diseases 0.000 claims description 7
229960004641 rituximab Drugs 0.000 claims description 7
206010010904 Convulsion Diseases 0.000 claims description 6
102000002791 Interleukin-8B Receptors Human genes 0.000 claims description 6
108010018951 Interleukin-8B Receptors Proteins 0.000 claims description 6
210000004940 Nucleus Anatomy 0.000 claims description 6
206010039911 Seizure Diseases 0.000 claims description 6
230000000973 chemotherapeutic Effects 0.000 claims description 6
230000001506 immunosuppresive Effects 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
230000035533 AUC Effects 0.000 claims description 5
208000001284 Hemoglobinopathy Diseases 0.000 claims description 5
102000018358 Immunoglobulins Human genes 0.000 claims description 5
108060003951 Immunoglobulins Proteins 0.000 claims description 5
230000002159 abnormal effect Effects 0.000 claims description 5
230000001186 cumulative Effects 0.000 claims description 5
201000003923 hemoglobinopathy Diseases 0.000 claims description 5
102100009664 CXCL2 Human genes 0.000 claims description 4
101700075102 CXCL2 Proteins 0.000 claims description 4
HPHUVLMMVZITSG-ZCFIWIBFSA-N Levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 claims description 4
238000001990 intravenous administration Methods 0.000 claims description 4
229960004002 levetiracetam Drugs 0.000 claims description 4
229940092117 ATGAM Drugs 0.000 claims description 3
210000002351 Embryonic Muscle Cell Anatomy 0.000 claims description 3
230000003042 antagnostic Effects 0.000 claims description 3
239000005557 antagonist Substances 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
229940079593 drugs Drugs 0.000 claims description 3
RTGDFNSFWBGLEC-UHFFFAOYSA-N CellCept Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1CC=C(C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-UHFFFAOYSA-N 0.000 claims description 2
229940107810 Cellcept Drugs 0.000 claims description 2
229940062717 Keppra Drugs 0.000 claims description 2
229940101533 Mesnex Drugs 0.000 claims description 2
229960002715 Nicotine Drugs 0.000 claims description 2
229930015196 nicotine Natural products 0.000 claims description 2
239000000651 prodrug Substances 0.000 claims description 2
229940002612 prodrugs Drugs 0.000 claims description 2
230000000644 propagated Effects 0.000 claims description 2
XOGTZOOQQBDUSI-UHFFFAOYSA-M sodium;2-sulfanylethanesulfonate Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 claims description 2
125000001424 substituent group Chemical group 0.000 description 84
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 70
125000005843 halogen group Chemical group 0.000 description 69
125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 55
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 52
RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 51
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 48
125000004076 pyridyl group Chemical group 0.000 description 46
125000001544 thienyl group Chemical group 0.000 description 45
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 43
229920000023 polynucleotide Polymers 0.000 description 38
239000002157 polynucleotide Substances 0.000 description 38
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 37
125000003545 alkoxy group Chemical group 0.000 description 36
229910052757 nitrogen Inorganic materials 0.000 description 35
125000006650 (C2-C4) alkynyl group Chemical group 0.000 description 34
125000004122 cyclic group Chemical group 0.000 description 34
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 34
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 33
229920003013 deoxyribonucleic acid Polymers 0.000 description 33
241000700605 Viruses Species 0.000 description 32
125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 32
229920000033 CRISPR Polymers 0.000 description 31
238000000034 method Methods 0.000 description 30
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 30
230000014509 gene expression Effects 0.000 description 29
VZIHTQKMHLOIII-UHFFFAOYSA-N 3,5-dihydro-2H-furan Chemical group [CH]1CCOC1 VZIHTQKMHLOIII-UHFFFAOYSA-N 0.000 description 26
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 26
125000005955 1H-indazolyl group Chemical group 0.000 description 24
108010082319 CRISPR-Associated Protein 9 Proteins 0.000 description 24
125000004429 atoms Chemical group 0.000 description 24
230000002708 enhancing Effects 0.000 description 21
235000018102 proteins Nutrition 0.000 description 21
102000004169 proteins and genes Human genes 0.000 description 21
108090000623 proteins and genes Proteins 0.000 description 21
125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 20
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 19
210000004962 mammalian cells Anatomy 0.000 description 19
125000000335 thiazolyl group Chemical group 0.000 description 19
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 18
125000003373 pyrazinyl group Chemical group 0.000 description 18
125000000714 pyrimidinyl group Chemical group 0.000 description 18
101700051117 FUT1 Proteins 0.000 description 17
239000000427 antigen Substances 0.000 description 17
102000038129 antigens Human genes 0.000 description 17
108091007172 antigens Proteins 0.000 description 17
230000027455 binding Effects 0.000 description 17
210000003995 blood forming stem cell Anatomy 0.000 description 17
125000002883 imidazolyl group Chemical group 0.000 description 17
PZHIWRCQKBBTOW-UHFFFAOYSA-N 1-ethoxybutane Chemical compound CCCCOCC PZHIWRCQKBBTOW-UHFFFAOYSA-N 0.000 description 16
238000010354 CRISPR gene editing Methods 0.000 description 16
239000003623 enhancer Substances 0.000 description 16
125000002541 furyl group Chemical group 0.000 description 16
238000010362 genome editing Methods 0.000 description 16
102100008333 THY1 Human genes 0.000 description 15
101700026084 THY1 Proteins 0.000 description 15
229910052799 carbon Inorganic materials 0.000 description 15
125000004356 hydroxy functional group Chemical group O* 0.000 description 15
239000000126 substance Substances 0.000 description 15
125000000008 (C1-C10) alkyl group Chemical group 0.000 description 14
125000006656 (C2-C4) alkenyl group Chemical group 0.000 description 14
230000022131 cell cycle Effects 0.000 description 14
239000011886 peripheral blood Substances 0.000 description 14
108020005004 Guide RNA Proteins 0.000 description 13
229920002391 Guide RNA Polymers 0.000 description 13
238000002744 homologous recombination Methods 0.000 description 13
230000035897 transcription Effects 0.000 description 13
125000004552 isoquinolin-4-yl group Chemical group C1=NC=C(C2=CC=CC=C12)* 0.000 description 12
125000004419 alkynylene group Chemical group 0.000 description 11
235000001014 amino acid Nutrition 0.000 description 11
125000004432 carbon atoms Chemical group C* 0.000 description 11
230000000694 effects Effects 0.000 description 11
125000005647 linker group Chemical group 0.000 description 11
230000035772 mutation Effects 0.000 description 11
108020004707 nucleic acids Proteins 0.000 description 11
150000007523 nucleic acids Chemical class 0.000 description 11
210000001185 Bone Marrow Anatomy 0.000 description 10
206010068051 Chimerism Diseases 0.000 description 10
229920001850 Nucleic acid sequence Polymers 0.000 description 10
150000001413 amino acids Chemical group 0.000 description 10
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
201000010874 syndrome Diseases 0.000 description 10
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 9
229940100198 ALKYLATING AGENTS Drugs 0.000 description 9
125000004450 alkenylene group Chemical group 0.000 description 9
125000003118 aryl group Chemical group 0.000 description 9
125000005842 heteroatoms Chemical group 0.000 description 9
230000037361 pathway Effects 0.000 description 9
125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 8
210000000601 Blood Cells Anatomy 0.000 description 8
210000000170 Cell Membrane Anatomy 0.000 description 8
102000004127 Cytokines Human genes 0.000 description 8
108090000695 Cytokines Proteins 0.000 description 8
102000014961 Protein Precursors Human genes 0.000 description 8
108010078762 Protein Precursors Proteins 0.000 description 8
125000003342 alkenyl group Chemical group 0.000 description 8
230000001580 bacterial Effects 0.000 description 8
125000001309 chloro group Chemical group Cl* 0.000 description 8
238000003776 cleavage reaction Methods 0.000 description 8
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 8
125000001153 fluoro group Chemical group F* 0.000 description 8
125000004474 heteroalkylene group Chemical group 0.000 description 8
230000001404 mediated Effects 0.000 description 8
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 8
125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 8
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 8
229920000160 (ribonucleotides)n+m Polymers 0.000 description 7
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 7
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 7
108090000790 Enzymes Proteins 0.000 description 7
125000000304 alkynyl group Chemical group 0.000 description 7
230000000295 complement Effects 0.000 description 7
230000002354 daily Effects 0.000 description 7
201000002138 hematopoietic system disease Diseases 0.000 description 7
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 7
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
230000036961 partial Effects 0.000 description 7
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
238000001890 transfection Methods 0.000 description 7
230000003612 virological Effects 0.000 description 7
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 6
208000007502 Anemia Diseases 0.000 description 6
206010024324 Leukaemias Diseases 0.000 description 6
210000004698 Lymphocytes Anatomy 0.000 description 6
206010039491 Sarcoma Diseases 0.000 description 6
102100016214 THPO Human genes 0.000 description 6
101710040065 THPO Proteins 0.000 description 6
101700076107 TPO Proteins 0.000 description 6
229920002397 Thermoplastic olefin Polymers 0.000 description 6
125000002947 alkylene group Chemical group 0.000 description 6
230000002950 deficient Effects 0.000 description 6
201000001981 dermatomyositis Diseases 0.000 description 6
238000010353 genetic engineering Methods 0.000 description 6
230000005017 genetic modification Effects 0.000 description 6
235000013617 genetically modified food Nutrition 0.000 description 6
239000003102 growth factor Substances 0.000 description 6
239000002609 media Substances 0.000 description 6
230000001400 myeloablative Effects 0.000 description 6
229910052760 oxygen Inorganic materials 0.000 description 6
230000002062 proliferating Effects 0.000 description 6
230000001105 regulatory Effects 0.000 description 6
238000003860 storage Methods 0.000 description 6
238000006467 substitution reaction Methods 0.000 description 6
229910052717 sulfur Inorganic materials 0.000 description 6
210000004369 Blood Anatomy 0.000 description 5
241000701022 Cytomegalovirus Species 0.000 description 5
229920001272 Exogenous DNA Polymers 0.000 description 5
101700080605 NUC1 Proteins 0.000 description 5
108009000261 Non-homologous end joining Proteins 0.000 description 5
150000001412 amines Chemical group 0.000 description 5
UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
239000008280 blood Substances 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
230000003993 interaction Effects 0.000 description 5
239000002502 liposome Substances 0.000 description 5
102000027675 major histocompatibility complex family Human genes 0.000 description 5
125000002950 monocyclic group Chemical group 0.000 description 5
101700006494 nucA Proteins 0.000 description 5
229920000768 polyamine Polymers 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
108090000765 processed proteins & peptides Proteins 0.000 description 5
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
239000011593 sulfur Substances 0.000 description 5
102000003995 transcription factors Human genes 0.000 description 5
108090000464 transcription factors Proteins 0.000 description 5
125000003161 (C1-C6) alkylene group Chemical group 0.000 description 4
125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 4
241000282693 Cercopithecidae Species 0.000 description 4
241000282412 Homo Species 0.000 description 4
206010061598 Immunodeficiency Diseases 0.000 description 4
208000003456 Juvenile Arthritis Diseases 0.000 description 4
206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 4
229920002248 Nuclear DNA Polymers 0.000 description 4
206010035226 Plasma cell myeloma Diseases 0.000 description 4
210000000603 Stem Cell Niche Anatomy 0.000 description 4
108010017070 Zinc Finger Nucleases Proteins 0.000 description 4
239000011324 bead Substances 0.000 description 4
238000004520 electroporation Methods 0.000 description 4
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 4
230000012010 growth Effects 0.000 description 4
229910052736 halogen Inorganic materials 0.000 description 4
150000002367 halogens Chemical group 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
238000001638 lipofection Methods 0.000 description 4
230000002503 metabolic Effects 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000006011 modification reaction Methods 0.000 description 4
230000000051 modifying Effects 0.000 description 4
201000006417 multiple sclerosis Diseases 0.000 description 4
150000002829 nitrogen Chemical group 0.000 description 4
239000001301 oxygen Substances 0.000 description 4
MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 4
230000001575 pathological Effects 0.000 description 4
230000001737 promoting Effects 0.000 description 4
KFFMWJLUQMFKOH-UHFFFAOYSA-N pyrrol-1-ide Chemical compound C=1C=C[N-]C=1 KFFMWJLUQMFKOH-UHFFFAOYSA-N 0.000 description 4
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 4
150000003254 radicals Chemical class 0.000 description 4
230000004044 response Effects 0.000 description 4
239000000758 substrate Substances 0.000 description 4
LKTNEXPODAWWFM-UHFFFAOYSA-N 2-methyl-N-[2-methyl-4-[(2-methylphenyl)diazenyl]phenyl]pyrazole-3-carboxamide Chemical compound CC1=CC=CC=C1N=NC(C=C1C)=CC=C1NC(=O)C1=CC=NN1C LKTNEXPODAWWFM-UHFFFAOYSA-N 0.000 description 3
206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 3
206010002967 Aplastic anaemia Diseases 0.000 description 3
206010050245 Autoimmune thrombocytopenia Diseases 0.000 description 3
102100013077 CD4 Human genes 0.000 description 3
101700022938 CD4 Proteins 0.000 description 3
206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 3
206010053138 Congenital aplastic anaemia Diseases 0.000 description 3
206010011401 Crohn's disease Diseases 0.000 description 3
206010012818 Diffuse large B-cell lymphoma Diseases 0.000 description 3
229940096919 Glycogen Drugs 0.000 description 3
BYSGBSNPRWKUQH-UJDJLXLFSA-N Glycogen Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)O1 BYSGBSNPRWKUQH-UJDJLXLFSA-N 0.000 description 3
229920002527 Glycogen Polymers 0.000 description 3
102100019441 ITGAM Human genes 0.000 description 3
101710006572 ITGAM Proteins 0.000 description 3
102000004854 Immunoglobulin M Human genes 0.000 description 3
108090001096 Immunoglobulin M Proteins 0.000 description 3
108090001005 Interleukin-6 Proteins 0.000 description 3
208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 3
208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 3
210000000265 Leukocytes Anatomy 0.000 description 3
206010049646 Lymphohistiocytosis Diseases 0.000 description 3
206010025323 Lymphomas Diseases 0.000 description 3
210000003593 Megakaryocytes Anatomy 0.000 description 3
108020004999 Messenger RNA Proteins 0.000 description 3
208000002678 Mucopolysaccharidosis Diseases 0.000 description 3
206010028093 Mucopolysaccharidosis Diseases 0.000 description 3
206010029260 Neuroblastoma Diseases 0.000 description 3
206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 3
208000002865 Osteopetrosis Diseases 0.000 description 3
206010025310 Other lymphomas Diseases 0.000 description 3
229940067631 Phospholipids Drugs 0.000 description 3
210000002826 Placenta Anatomy 0.000 description 3
YIQPUIGJQJDJOS-UHFFFAOYSA-N Plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 3
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 3
208000002098 Purpura, Thrombocytopenic, Idiopathic Diseases 0.000 description 3
210000002966 Serum Anatomy 0.000 description 3
208000009642 Severe combined immunodeficiency due to adenosine deaminase deficiency Diseases 0.000 description 3
208000007056 Sickle Cell Anemia Diseases 0.000 description 3
241000580858 Simian-Human immunodeficiency virus Species 0.000 description 3
208000010346 Sphingolipidosis Diseases 0.000 description 3
238000010459 TALEN Methods 0.000 description 3
108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 3
102000008579 Transposases Human genes 0.000 description 3
108010020764 Transposases Proteins 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
201000005510 acute lymphocytic leukemia Diseases 0.000 description 3
125000006193 alkinyl group Chemical group 0.000 description 3
125000000732 arylene group Chemical group 0.000 description 3
125000002619 bicyclic group Chemical group 0.000 description 3
125000002091 cationic group Chemical group 0.000 description 3
201000006934 chronic myeloid leukemia Diseases 0.000 description 3
125000002993 cycloalkylene group Chemical group 0.000 description 3
210000000222 eosinocyte Anatomy 0.000 description 3
210000003527 eukaryotic cell Anatomy 0.000 description 3
238000000684 flow cytometry Methods 0.000 description 3
125000006588 heterocycloalkylene group Chemical group 0.000 description 3
150000004677 hydrates Chemical class 0.000 description 3
230000001965 increased Effects 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 3
230000005291 magnetic Effects 0.000 description 3
239000003550 marker Substances 0.000 description 3
239000000463 material Substances 0.000 description 3
229920002106 messenger RNA Polymers 0.000 description 3
230000002025 microglial Effects 0.000 description 3
125000004433 nitrogen atoms Chemical group N* 0.000 description 3
210000000056 organs Anatomy 0.000 description 3
150000003904 phospholipids Chemical class 0.000 description 3
229920002401 polyacrylamide Polymers 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
238000000746 purification Methods 0.000 description 3
150000003212 purines Chemical class 0.000 description 3
238000006798 ring closing metathesis reaction Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
201000001307 sphingolipidosis Diseases 0.000 description 3
201000000596 systemic lupus erythematosus Diseases 0.000 description 3
241000701161 unidentified adenovirus Species 0.000 description 3
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
108020005345 3' Untranslated Regions Proteins 0.000 description 2
108020003589 5' Untranslated Regions Proteins 0.000 description 2
102100001249 ALB Human genes 0.000 description 2
101710027066 ALB Proteins 0.000 description 2
206010000880 Acute myeloid leukaemia Diseases 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
229940064005 Antibiotic throat preparations Drugs 0.000 description 2
229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 2
229940042052 Antibiotics for systemic use Drugs 0.000 description 2
229940042786 Antitubercular Antibiotics Drugs 0.000 description 2
241000701844 Bacillus virus phi29 Species 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
101700034624 CASP3 Proteins 0.000 description 2
102100003814 CASP3 Human genes 0.000 description 2
229960005091 Chloramphenicol Drugs 0.000 description 2
WIIZWVCIJKGZOK-RKDXNWHRSA-N Chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
210000000349 Chromosomes Anatomy 0.000 description 2
206010009887 Colitis Diseases 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
206010012601 Diabetes mellitus Diseases 0.000 description 2
201000004449 Diamond-Blackfan anemia Diseases 0.000 description 2
206010016256 Fatigue Diseases 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
101700030975 GALC Proteins 0.000 description 2
102100017667 GALC Human genes 0.000 description 2
229940093922 Gynecological Antibiotics Drugs 0.000 description 2
102100020458 HLA-A Human genes 0.000 description 2
108010075704 HLA-A Antigens Proteins 0.000 description 2
102100020459 HLA-B Human genes 0.000 description 2
108010058607 HLA-B Antigens Proteins 0.000 description 2
102000006354 HLA-DR Antigens Human genes 0.000 description 2
108010058597 HLA-DR Antigens Proteins 0.000 description 2
210000003780 Hair Follicle Anatomy 0.000 description 2
210000000777 Hematopoietic System Anatomy 0.000 description 2
108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
102100016985 KIT Human genes 0.000 description 2
101710009391 KIT Proteins 0.000 description 2
101710028765 KITLG Proteins 0.000 description 2
SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
229920001320 Leader sequence (mRNA) Polymers 0.000 description 2
241000713666 Lentivirus Species 0.000 description 2
208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 2
210000004185 Liver Anatomy 0.000 description 2
210000004072 Lung Anatomy 0.000 description 2
101700052785 Ly6a Proteins 0.000 description 2
210000002901 Mesenchymal Stem Cells Anatomy 0.000 description 2
FTJHKZQHQDKPFJ-UHFFFAOYSA-M NC(=O)NNC([O-])=O Chemical compound NC(=O)NNC([O-])=O FTJHKZQHQDKPFJ-UHFFFAOYSA-M 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
210000002997 Osteoclasts Anatomy 0.000 description 2
208000008601 Polycythemia Diseases 0.000 description 2
102100018787 RPS19 Human genes 0.000 description 2
101710007829 RPS19 Proteins 0.000 description 2
108020005091 Replication Origin Proteins 0.000 description 2
101700068919 SCAL1 Proteins 0.000 description 2
206010039710 Scleroderma Diseases 0.000 description 2
208000002491 Severe Combined Immunodeficiency Diseases 0.000 description 2
206010042953 Systemic sclerosis Diseases 0.000 description 2
208000002903 Thalassemia Diseases 0.000 description 2
229920000401 Three prime untranslated region Polymers 0.000 description 2
229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 2
206010052779 Transplant rejections Diseases 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
208000007089 Vaccinia Diseases 0.000 description 2
206010046865 Vaccinia virus infection Diseases 0.000 description 2
208000006110 Wiskott-Aldrich Syndrome Diseases 0.000 description 2
102000001392 Wiskott-Aldrich Syndrome Protein Human genes 0.000 description 2
108010093528 Wiskott-Aldrich Syndrome Protein Proteins 0.000 description 2
KMLHDSULFOYCCK-UHFFFAOYSA-N [3-(aminomethyl)-2-(pyridin-2-ylmethyl)phenyl]methanamine Chemical compound NCC1=CC=CC(CN)=C1CC1=CC=CC=N1 KMLHDSULFOYCCK-UHFFFAOYSA-N 0.000 description 2
150000001241 acetals Chemical class 0.000 description 2
230000001154 acute Effects 0.000 description 2
125000002252 acyl group Chemical group 0.000 description 2
125000004442 acylamino group Chemical group 0.000 description 2
125000004423 acyloxy group Chemical group 0.000 description 2
229940050528 albumin Drugs 0.000 description 2
125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
125000002877 alkyl aryl group Chemical group 0.000 description 2
125000005213 alkyl heteroaryl group Chemical group 0.000 description 2
125000003275 alpha amino acid group Chemical group 0.000 description 2
150000007854 aminals Chemical class 0.000 description 2
125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 2
239000007640 basal medium Substances 0.000 description 2
KXDAEFPNCMNJSK-UHFFFAOYSA-N benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
238000004166 bioassay Methods 0.000 description 2
230000003115 biocidal Effects 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
201000002393 blood protein disease Diseases 0.000 description 2
210000004271 bone marrow stromal cells Anatomy 0.000 description 2
238000010322 bone marrow transplantation Methods 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
150000003857 carboxamides Chemical class 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
101700056051 cas9 Proteins 0.000 description 2
230000002860 competitive Effects 0.000 description 2
PMATZTZNYRCHOR-UHFFFAOYSA-N cyclosporine A Chemical compound CCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-UHFFFAOYSA-N 0.000 description 2
229910003460 diamond Inorganic materials 0.000 description 2
239000010432 diamond Substances 0.000 description 2
201000009910 diseases by infectious agent Diseases 0.000 description 2
241001493065 dsRNA viruses Species 0.000 description 2
230000005684 electric field Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
230000002489 hematologic Effects 0.000 description 2
125000005549 heteroarylene group Chemical group 0.000 description 2
OAKJQQAXSVQMHS-UHFFFAOYSA-O hydrazinium(1+) Chemical compound [NH3+]N OAKJQQAXSVQMHS-UHFFFAOYSA-O 0.000 description 2
125000004435 hydrogen atoms Chemical group [H]* 0.000 description 2
125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000016784 immunoglobulin production Effects 0.000 description 2
125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 description 2
125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 2
239000000411 inducer Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
229940079866 intestinal antibiotics Drugs 0.000 description 2
229910052740 iodine Inorganic materials 0.000 description 2
229960000318 kanamycin Drugs 0.000 description 2
150000003951 lactams Chemical class 0.000 description 2
150000002596 lactones Chemical class 0.000 description 2
239000003446 ligand Substances 0.000 description 2
230000000670 limiting Effects 0.000 description 2
230000003211 malignant Effects 0.000 description 2
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
230000003458 metachromatic Effects 0.000 description 2
201000009251 multiple myeloma Diseases 0.000 description 2
201000003793 myelodysplastic syndrome Diseases 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
230000030147 nuclear export Effects 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
229940005935 ophthalmologic Antibiotics Drugs 0.000 description 2
230000002148 osteoclast Effects 0.000 description 2
125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 2
230000001402 polyadenylating Effects 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000000047 product Substances 0.000 description 2
WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
230000002629 repopulating Effects 0.000 description 2
230000001568 sexual Effects 0.000 description 2
230000011664 signaling Effects 0.000 description 2
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
230000004083 survival Effects 0.000 description 2
230000002459 sustained Effects 0.000 description 2
201000009594 systemic scleroderma Diseases 0.000 description 2
230000001225 therapeutic Effects 0.000 description 2
150000003555 thioacetals Chemical class 0.000 description 2
125000003396 thiol group Chemical group [H]S* 0.000 description 2
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
230000005026 transcription initiation Effects 0.000 description 2
230000001131 transforming Effects 0.000 description 2
125000004953 trihalomethyl group Chemical group 0.000 description 2
241001529453 unidentified herpesvirus Species 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
230000017613 viral reproduction Effects 0.000 description 2
FOSDRKVGBZLRRC-QMMNWOAZSA-N (1R,2R)-1-N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-1-N-(5,6,7,8-tetrahydroquinolin-8-yl)cyclopentane-1,2-diamine Chemical compound N[C@@H]1CCC[C@H]1N(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 FOSDRKVGBZLRRC-QMMNWOAZSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2R,3R,4S,5R,6S)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2S,3R,4S,5R,6R)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2R,3R,4S,5R,6R)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
RSGZLNITLGQDQL-XGLRFROISA-N (2S)-2-amino-N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydroquinolin-8-yl)propanamide Chemical compound C1CCC2=CC=CN=C2C1N(C(=O)[C@@H](N)C)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 RSGZLNITLGQDQL-XGLRFROISA-N 0.000 description 1
JMISKXGBLMKCBE-PMCHYTPCSA-N (2S)-N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydroquinolin-8-yl)pyrrolidine-2-carboxamide Chemical compound C=1C=C(CNCC=2N=CC=CC=2)C=CC=1CN(C1C2=NC=CC=C2CCC1)C(=O)[C@@H]1CCCN1 JMISKXGBLMKCBE-PMCHYTPCSA-N 0.000 description 1
125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 description 1
HLRWRACNIJFYEO-UHFFFAOYSA-N 1,4,7,10-tetrazacyclotetradecane Chemical compound C1CCNCCNCCNCCNC1 HLRWRACNIJFYEO-UHFFFAOYSA-N 0.000 description 1
LXUJUJYVZSBOKU-UHFFFAOYSA-N 1,4,7-triazacyclotetradecane Chemical compound C1CCCNCCNCCNCCC1 LXUJUJYVZSBOKU-UHFFFAOYSA-N 0.000 description 1
QPFUQMRWZANCBG-UHFFFAOYSA-N 1-[1-(1,4,8,11-tetrazacyclotetradec-1-yl)hexan-2-yl]-1,4,8,11-tetrazacyclotetradecane Chemical compound C1CCNCCNCCCNCCN1C(CCCC)CN1CCCNCCNCCCNCC1 QPFUQMRWZANCBG-UHFFFAOYSA-N 0.000 description 1
GVPVISVGQUQSSG-UHFFFAOYSA-N 1-[2-(1,4,8,11-tetrazacyclotetradec-1-yl)ethyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound C1CCNCCNCCCNCCN1CCN1CCCNCCNCCCNCC1 GVPVISVGQUQSSG-UHFFFAOYSA-N 0.000 description 1
PMGQWFFOFZQXSJ-UHFFFAOYSA-N 1-[4-(1,7-diazacyclotetradec-4-ylmethyl)phenyl]-N-(pyridin-2-ylmethyl)methanamine Chemical compound C=1C=C(CC2CCNCCCCCCCNCC2)C=CC=1CNCC1=CC=CC=N1 PMGQWFFOFZQXSJ-UHFFFAOYSA-N 0.000 description 1
GKJYLJLZQLRHLX-UHFFFAOYSA-N 1-[4-[(11,11-difluoro-1,4,7-triazacyclotetradec-4-yl)methyl]phenyl]-N-(pyridin-2-ylmethyl)methanamine Chemical compound C1CNCCCC(F)(F)CCCNCCN1CC(C=C1)=CC=C1CNCC1=CC=CC=N1 GKJYLJLZQLRHLX-UHFFFAOYSA-N 0.000 description 1
PTDLVNBLFNWNGP-UHFFFAOYSA-N 1-[[2,3,4,6-tetrachloro-5-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound ClC=1C(CN2CCNCCCNCCNCCC2)=C(Cl)C(Cl)=C(Cl)C=1CN1CCCNCCNCCCNCC1 PTDLVNBLFNWNGP-UHFFFAOYSA-N 0.000 description 1
SEFLKOOVNJZTFY-UHFFFAOYSA-N 1-[[2,3,5,6-tetrafluoro-4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound FC=1C(F)=C(CN2CCNCCCNCCNCCC2)C(F)=C(F)C=1CN1CCCNCCNCCCNCC1 SEFLKOOVNJZTFY-UHFFFAOYSA-N 0.000 description 1
NYQPBUORMFOXKK-UHFFFAOYSA-N 1-[[2,5-dichloro-4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound ClC=1C=C(CN2CCNCCCNCCNCCC2)C(Cl)=CC=1CN1CCCNCCNCCCNCC1 NYQPBUORMFOXKK-UHFFFAOYSA-N 0.000 description 1
GBUVEYKYEYRGEU-UHFFFAOYSA-N 1-[[2,5-dimethyl-4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound CC=1C=C(CN2CCNCCCNCCNCCC2)C(C)=CC=1CN1CCCNCCNCCCNCC1 GBUVEYKYEYRGEU-UHFFFAOYSA-N 0.000 description 1
PGEQTORRJVBGAW-UHFFFAOYSA-N 1-[[2-[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)pyridin-2-yl]pyridin-4-yl]methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound C=1C=NC(C=2N=CC=C(CN3CCNCCCNCCNCCC3)C=2)=CC=1CN1CCCNCCNCCCNCC1 PGEQTORRJVBGAW-UHFFFAOYSA-N 0.000 description 1
CGBPRRHXVCXIKY-UHFFFAOYSA-N 1-[[2-bromo-4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C(Br)=CC=1CN1CCCNCCNCCCNCC1 CGBPRRHXVCXIKY-UHFFFAOYSA-N 0.000 description 1
PXTXSIAYIFRMDE-UHFFFAOYSA-N 1-[[3-(1,4,7,10-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,7,10-tetrazacyclotetradecane Chemical compound C=1C=CC(CN2CCNCCNCCNCCCC2)=CC=1CN1CCCCNCCNCCNCC1 PXTXSIAYIFRMDE-UHFFFAOYSA-N 0.000 description 1
TWROELGOZKDRSL-UHFFFAOYSA-N 1-[[3-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound C=1C=CC(CN2CCNCCCNCCNCCC2)=CC=1CN1CCCNCCNCCCNCC1 TWROELGOZKDRSL-UHFFFAOYSA-N 0.000 description 1
UPPOFVSOKBVXDP-UHFFFAOYSA-N 1-[[3-(1,5,9-triazacyclododec-1-ylmethyl)phenyl]methyl]-1,5,9-triazacyclododecane Chemical compound C=1C=CC(CN2CCCNCCCNCCC2)=CC=1CN1CCCNCCCNCCC1 UPPOFVSOKBVXDP-UHFFFAOYSA-N 0.000 description 1
HMIWFQMAZGWHMZ-UHFFFAOYSA-N 1-[[3-[3-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound C=1C=CC(C=2C=C(CN3CCNCCCNCCNCCC3)C=CC=2)=CC=1CN1CCCNCCNCCCNCC1 HMIWFQMAZGWHMZ-UHFFFAOYSA-N 0.000 description 1
PEVCHIZAJILPKB-UHFFFAOYSA-N 1-[[3-nitro-5-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound C=1C(CN2CCNCCCNCCNCCC2)=CC([N+](=O)[O-])=CC=1CN1CCCNCCNCCCNCC1 PEVCHIZAJILPKB-UHFFFAOYSA-N 0.000 description 1
BNXRQMCWXHZHTF-UHFFFAOYSA-N 1-[[4-(1,4,7,10-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]-1,4,7,10-tetrazacyclotetradecane Chemical compound C=1C=C(CN2CCNCCNCCNCCCC2)C=CC=1CN1CCCCNCCNCCNCC1 BNXRQMCWXHZHTF-UHFFFAOYSA-N 0.000 description 1
QNIZOKGSHPITQD-UHFFFAOYSA-N 1-[[4-(1,4,7,11-tetrazacyclotetradec-11-ylmethyl)phenyl]methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCNCCC1 QNIZOKGSHPITQD-UHFFFAOYSA-N 0.000 description 1
VABFVYHLECCOIA-UHFFFAOYSA-N 1-[[5-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)thiophen-2-yl]methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)SC=1CN1CCCNCCNCCCNCC1 VABFVYHLECCOIA-UHFFFAOYSA-N 0.000 description 1
BKJDPXSXCZMISN-UHFFFAOYSA-N 1-[[6-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)pyridin-2-yl]methyl]-1,4,8,11-tetrazacyclotetradecane Chemical compound C=1C=CC(CN2CCNCCCNCCNCCC2)=NC=1CN1CCCNCCNCCCNCC1 BKJDPXSXCZMISN-UHFFFAOYSA-N 0.000 description 1
VHUNAUGRQAADNH-UHFFFAOYSA-N 1-benzyl-N-(pyridin-2-ylmethyl)-N-[[3-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]pyrrolidin-3-amine Chemical compound C=1C=CC(CN(CC=2N=CC=CC=2)C2CN(CC=3C=CC=CC=3)CC2)=CC=1CNCC1=CC=CC=N1 VHUNAUGRQAADNH-UHFFFAOYSA-N 0.000 description 1
VXNZUUAINFGPBY-UHFFFAOYSA-N 1-butene Chemical group CCC=C VXNZUUAINFGPBY-UHFFFAOYSA-N 0.000 description 1
BJXXQCURPZWADT-UHFFFAOYSA-N 1-methyl-N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-1,2,3,4-tetrahydronaphthalen-2-amine Chemical compound C1CC2=CC=CC=C2C(C)C1NCC(C=C1)=CC=C1CNCC1=CC=CC=N1 BJXXQCURPZWADT-UHFFFAOYSA-N 0.000 description 1
HOXGWRSXHJHFMF-UHFFFAOYSA-N 1-phenyl-N-(pyridin-2-ylmethyl)-N-[[3-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]ethanamine Chemical compound C=1C=CC=CC=1C(C)N(CC=1N=CC=CC=1)CC(C=1)=CC=CC=1CNCC1=CC=CC=N1 HOXGWRSXHJHFMF-UHFFFAOYSA-N 0.000 description 1
YRMKTQNDPSHONR-UHFFFAOYSA-N 1-phenyl-N-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]methanamine Chemical compound C=1C=CC=CC=1CNCC(C=C1)=CC=C1CN1CCCNCCNCCCNCC1 YRMKTQNDPSHONR-UHFFFAOYSA-N 0.000 description 1
IAGWLDWQRRSAIK-UHFFFAOYSA-N 11-[[4-(1,4,7,11-tetrazacyclotetradec-11-ylmethyl)phenyl]methyl]-1,4,7,11-tetrazacyclotetradecane Chemical compound C=1C=C(CN2CCCNCCNCCNCCC2)C=CC=1CN1CCCNCCNCCNCCC1 IAGWLDWQRRSAIK-UHFFFAOYSA-N 0.000 description 1
JUUZQMUWOVDZSD-UHFFFAOYSA-N 1H-imidazole;pyrazine Chemical compound C1=CNC=N1.C1=CN=CC=N1 JUUZQMUWOVDZSD-UHFFFAOYSA-N 0.000 description 1
SBPIDKODQVLBGV-UHFFFAOYSA-N 1H-imidazole;pyridine Chemical compound C1=CNC=N1.C1=CC=NC=C1 SBPIDKODQVLBGV-UHFFFAOYSA-N 0.000 description 1
125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
PMLZIXDTICSVTR-UHFFFAOYSA-N 2,9-bis(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)-1,10-phenanthroline Chemical compound C=1C=C2C=CC3=CC=C(CN4CCNCCCNCCNCCC4)N=C3C2=NC=1CN1CCCNCCNCCCNCC1 PMLZIXDTICSVTR-UHFFFAOYSA-N 0.000 description 1
YOMWIGRZWWQLIH-UHFFFAOYSA-N 2-(1H-imidazol-5-yl)-N-[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methyl]ethanamine Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CNCCC1=CN=CN1 YOMWIGRZWWQLIH-UHFFFAOYSA-N 0.000 description 1
VTSJNUHXDBTHAG-UHFFFAOYSA-N 2-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl-(5,6,7,8-tetrahydroquinolin-8-yl)amino]acetic acid Chemical compound C1CCC2=CC=CN=C2C1N(CC(=O)O)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 VTSJNUHXDBTHAG-UHFFFAOYSA-N 0.000 description 1
UQJUPEBNPXJTGH-UHFFFAOYSA-N 2-[[[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methylamino]methyl]aniline Chemical compound NC1=CC=CC=C1CNCC(C=C1)=CC=C1CN1CCNCCCNCCNCCC1 UQJUPEBNPXJTGH-UHFFFAOYSA-N 0.000 description 1
VRRHGRADXKUDHV-UHFFFAOYSA-N 2-amino-N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydroquinolin-8-yl)acetamide Chemical compound C1CCC2=CC=CN=C2C1N(C(=O)CN)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 VRRHGRADXKUDHV-UHFFFAOYSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 1
NOWAALMFKTVKNA-UHFFFAOYSA-N 2-phenyl-N-(pyridin-2-ylmethyl)-N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CN(CC=2N=CC=CC=2)C2C3=NC(=CC=C3CCC2)C=2C=CC=CC=2)C=CC=1CNCC1=CC=CC=N1 NOWAALMFKTVKNA-UHFFFAOYSA-N 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
SELQQIVKCRNKIT-UHFFFAOYSA-N 3-benzyl-1-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-1-(5,6,7,8-tetrahydroquinolin-8-yl)urea Chemical compound C=1C=C(CNCC=2N=CC=CC=2)C=CC=1CN(C1C2=NC=CC=C2CCC1)C(=O)NCC1=CC=CC=C1 SELQQIVKCRNKIT-UHFFFAOYSA-N 0.000 description 1
WVAWOUKVAOMCPU-UHFFFAOYSA-N 3-phenyl-1-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-1-(5,6,7,8-tetrahydroquinolin-8-yl)urea Chemical compound C=1C=C(CNCC=2N=CC=CC=2)C=CC=1CN(C1C2=NC=CC=C2CCC1)C(=O)NC1=CC=CC=C1 WVAWOUKVAOMCPU-UHFFFAOYSA-N 0.000 description 1
101700027111 3SA0 Proteins 0.000 description 1
AUZJRZXMZKCYBE-UHFFFAOYSA-N 4-[[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl-(5,6,7,8-tetrahydroquinolin-8-yl)amino]methyl]benzonitrile Chemical compound C1=CC(C#N)=CC=C1CN(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 AUZJRZXMZKCYBE-UHFFFAOYSA-N 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
SMVKJBOGSRFNKW-UHFFFAOYSA-N 4-methylbenzonitrile Chemical group [CH2]C1=CC=C(C#N)C=C1 SMVKJBOGSRFNKW-UHFFFAOYSA-N 0.000 description 1
CSUSIKFJDHUQEQ-UHFFFAOYSA-N 6-methoxy-N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-1,2,3,4-tetrahydronaphthalen-2-amine Chemical compound C1CC2=CC(OC)=CC=C2CC1NCC(C=C1)=CC=C1CNCC1=CC=CC=N1 CSUSIKFJDHUQEQ-UHFFFAOYSA-N 0.000 description 1
DKDLSEPIAWSONV-UHFFFAOYSA-N 7-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methylamino]-5,6,7,8-tetrahydronaphthalen-1-ol Chemical compound C1C=2C(O)=CC=CC=2CCC1NCC(C=C1)=CC=C1CNCC1=CC=CC=N1 DKDLSEPIAWSONV-UHFFFAOYSA-N 0.000 description 1
HRXBVPDNMXEMSA-UHFFFAOYSA-N 7-methoxy-N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-1,2,3,4-tetrahydronaphthalen-2-amine Chemical compound C1C2=CC(OC)=CC=C2CCC1NCC(C=C1)=CC=C1CNCC1=CC=CC=N1 HRXBVPDNMXEMSA-UHFFFAOYSA-N 0.000 description 1
101710006746 7.5K Proteins 0.000 description 1
XUQNFXXFHDZHNO-UHFFFAOYSA-N 8-fluoro-N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-1,2,3,4-tetrahydronaphthalen-2-amine Chemical compound C1C=2C(F)=CC=CC=2CCC1NCC(C=C1)=CC=C1CNCC1=CC=CC=N1 XUQNFXXFHDZHNO-UHFFFAOYSA-N 0.000 description 1
102100008450 AFP Human genes 0.000 description 1
241000432074 Adeno-associated virus Species 0.000 description 1
102000009914 Adenosine deaminases Human genes 0.000 description 1
108091022188 Adenosine deaminases Proteins 0.000 description 1
210000000577 Adipose Tissue Anatomy 0.000 description 1
210000004504 Adult Stem Cells Anatomy 0.000 description 1
208000008190 Agammaglobulinemia Diseases 0.000 description 1
102000005369 Aldehyde Dehydrogenase Human genes 0.000 description 1
108020002663 Aldehyde Dehydrogenase Proteins 0.000 description 1
108010090838 Alemtuzumab Proteins 0.000 description 1
229940045714 Alkyl sulfonate alkylating agents Drugs 0.000 description 1
241000710929 Alphavirus Species 0.000 description 1
210000004381 Amniotic Fluid Anatomy 0.000 description 1
208000009094 Anemia, Hemolytic, Autoimmune Diseases 0.000 description 1
208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 description 1
208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
206010003230 Arteritis Diseases 0.000 description 1
108009000203 Aryl Hydrocarbon Receptor Pathway Proteins 0.000 description 1
206010003827 Autoimmune hepatitis Diseases 0.000 description 1
229960002170 Azathioprine Drugs 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
206010004161 Basedow's disease Diseases 0.000 description 1
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
206010004661 Biliary cirrhosis primary Diseases 0.000 description 1
206010061590 Blood disease Diseases 0.000 description 1
241000714266 Bovine leukemia virus Species 0.000 description 1
208000000409 Breast Neoplasms Diseases 0.000 description 1
UPXZXNQWHQWURB-UXMRNZNESA-N C1CCC2=CC=CN=C2C1N(C(=O)[C@H](CC(N)=O)N)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 Chemical compound C1CCC2=CC=CN=C2C1N(C(=O)[C@H](CC(N)=O)N)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 UPXZXNQWHQWURB-UXMRNZNESA-N 0.000 description 1
102100005826 CD19 Human genes 0.000 description 1
101700087100 CD19 Proteins 0.000 description 1
102100019453 CD7 Human genes 0.000 description 1
101700063101 CD7 Proteins 0.000 description 1
102100008191 CD8A Human genes 0.000 description 1
101700054655 CD8A Proteins 0.000 description 1
201000002829 CREST syndrome Diseases 0.000 description 1
102100006400 CSF2 Human genes 0.000 description 1
102100002212 CXCR4 Human genes 0.000 description 1
101710003734 CXCR4 Proteins 0.000 description 1
229940112129 Campath Drugs 0.000 description 1
208000005846 Cardiomyopathy Diseases 0.000 description 1
210000001175 Cerebrospinal Fluid Anatomy 0.000 description 1
108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
229920002168 Chimeric RNA Polymers 0.000 description 1
229960004630 Chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
241000251730 Chondrichthyes Species 0.000 description 1
210000004252 Chorionic Villi Anatomy 0.000 description 1
229920002759 Circular DNA Polymers 0.000 description 1
108020004638 Circular DNA Proteins 0.000 description 1
229920002839 Cis-regulatory element Polymers 0.000 description 1
235000008733 Citrus aurantifolia Nutrition 0.000 description 1
PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
206010010099 Combined immunodeficiency Diseases 0.000 description 1
229920000453 Consensus sequence Polymers 0.000 description 1
241000711573 Coronaviridae Species 0.000 description 1
230000033616 DNA repair Effects 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
206010061811 Demyelinating polyneuropathy Diseases 0.000 description 1
210000003074 Dental Pulp Anatomy 0.000 description 1
208000000849 Developmental Bone Disease Diseases 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
XQTWDDCIUJNLTR-CVHRZJFOSA-N Doxycycline Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
229960003722 Doxycycline Drugs 0.000 description 1
206010014004 Ear disease Diseases 0.000 description 1
210000003027 Ear, Inner Anatomy 0.000 description 1
230000035695 Efflux Effects 0.000 description 1
108090000394 Erythropoietin Proteins 0.000 description 1
102000003951 Erythropoietin Human genes 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
229950010333 Exalamide Drugs 0.000 description 1
201000004939 Fanconi anemia Diseases 0.000 description 1
210000000604 Fetal Stem Cells Anatomy 0.000 description 1
241000710831 Flavivirus Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
206010018048 Gaucher's disease Diseases 0.000 description 1
206010061979 Genital pain Diseases 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
206010018620 Goodpasture's syndrome Diseases 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
208000003807 Graves Disease Diseases 0.000 description 1
201000004779 Graves' disease Diseases 0.000 description 1
UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
208000005721 HIV Infections Diseases 0.000 description 1
102100020457 HLA-C Human genes 0.000 description 1
108010052199 HLA-C Antigens Proteins 0.000 description 1
230000036499 Half live Effects 0.000 description 1
208000002250 Hematologic Neoplasms Diseases 0.000 description 1
208000006454 Hepatitis Diseases 0.000 description 1
206010061205 Hereditary disease Diseases 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
206010020243 Hodgkin's disease Diseases 0.000 description 1
201000006743 Hodgkin's lymphoma Diseases 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
241000282620 Hylobates sp. Species 0.000 description 1
206010020983 Hypogammaglobulinaemia Diseases 0.000 description 1
210000000987 Immune System Anatomy 0.000 description 1
206010021450 Immunodeficiency congenital Diseases 0.000 description 1
206010052739 Immunodeficiency disorder Diseases 0.000 description 1
206010021460 Immunodeficiency syndrome Diseases 0.000 description 1
231100000608 Immunotoxin Toxicity 0.000 description 1
108010004484 Immunotoxins Proteins 0.000 description 1
210000004263 Induced Pluripotent Stem Cells Anatomy 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010021972 Inflammatory bowel disease Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
108010002352 Interleukin-1 Proteins 0.000 description 1
108090000177 Interleukin-11 Proteins 0.000 description 1
108010002386 Interleukin-3 Proteins 0.000 description 1
210000004966 Intestinal stem cells Anatomy 0.000 description 1
201000007313 Kawasaki disease Diseases 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
206010024381 Leukodystrophy Diseases 0.000 description 1
206010068202 Leukodystrophy Diseases 0.000 description 1
208000002741 Leukoplakia Diseases 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
108090000028 MMP12 Proteins 0.000 description 1
102100000165 MS4A1 Human genes 0.000 description 1
101710010909 MS4A1 Proteins 0.000 description 1
206010064281 Malignant atrophic papulosis Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241000713821 Mason-Pfizer monkey virus Species 0.000 description 1
229960004961 Mechlorethamine Drugs 0.000 description 1
SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
210000004379 Membranes Anatomy 0.000 description 1
206010027183 Meniere's disease Diseases 0.000 description 1
229960004635 Mesna Drugs 0.000 description 1
108020004388 MicroRNAs Proteins 0.000 description 1
208000003250 Mixed Connective Tissue Disease Diseases 0.000 description 1
210000001616 Monocytes Anatomy 0.000 description 1
210000002161 Motor Neurons Anatomy 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
208000001725 Mucocutaneous Lymph Node Syndrome Diseases 0.000 description 1
210000002027 Muscle, Skeletal Anatomy 0.000 description 1
206010028372 Muscular weakness Diseases 0.000 description 1
210000003643 Myeloid Progenitor Cells Anatomy 0.000 description 1
206010028549 Myeloid leukaemia Diseases 0.000 description 1
206010028593 Myocardial disease Diseases 0.000 description 1
206010028640 Myopathy Diseases 0.000 description 1
YORNHNMWEWVKTM-UHFFFAOYSA-N N'-(1-methyl-3,4-dihydro-2H-quinolin-8-yl)-N-(pyridin-2-ylmethyl)-N'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]ethane-1,2-diamine Chemical compound C=12N(C)CCCC2=CC=CC=1N(CC=1C=CC(CNCC=2N=CC=CC=2)=CC=1)CCNCC1=CC=CC=N1 YORNHNMWEWVKTM-UHFFFAOYSA-N 0.000 description 1
OBCGVCHGTISUSB-UHFFFAOYSA-N N'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-N'-(5,6,7,8-tetrahydroquinolin-8-yl)ethane-1,2-diamine Chemical compound C1CCC2=CC=CN=C2C1N(CCN)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 OBCGVCHGTISUSB-UHFFFAOYSA-N 0.000 description 1
TWAJZSBBOJFYRN-UHFFFAOYSA-N N,N-bis[(2-methoxyphenyl)methyl]-N'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-N'-(5,6,7,8-tetrahydroquinolin-8-yl)ethane-1,2-diamine Chemical compound COC1=CC=CC=C1CN(CC=1C(=CC=CC=1)OC)CCN(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 TWAJZSBBOJFYRN-UHFFFAOYSA-N 0.000 description 1
YPTODVXKEJXEET-UHFFFAOYSA-N N-(1H-benzimidazol-2-ylmethyl)-N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CN(CC=2NC3=CC=CC=C3N=2)C2C3=NC=CC=C3CCC2)C=CC=1CNCC1=CC=CC=N1 YPTODVXKEJXEET-UHFFFAOYSA-N 0.000 description 1
CVCOZIAFFAJQFJ-UHFFFAOYSA-N N-(1H-imidazol-2-ylmethyl)-N'-(1-methyl-3,4-dihydro-2H-quinolin-8-yl)-N'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]ethane-1,2-diamine Chemical compound C=12N(C)CCCC2=CC=CC=1N(CC=1C=CC(CNCC=2N=CC=CC=2)=CC=1)CCNCC1=NC=CN1 CVCOZIAFFAJQFJ-UHFFFAOYSA-N 0.000 description 1
JNSXPMQONUZISJ-UHFFFAOYSA-N N-(1H-imidazol-2-ylmethyl)-N'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-N'-(1,2,3,4-tetrahydronaphthalen-1-yl)ethane-1,2-diamine Chemical compound N=1C=CNC=1CNCCN(C1C2=CC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 JNSXPMQONUZISJ-UHFFFAOYSA-N 0.000 description 1
WEZLIYLAGMXZGO-UHFFFAOYSA-N N-(1H-imidazol-2-ylmethyl)-N'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-N'-(5,6,7,8-tetrahydroquinolin-8-yl)ethane-1,2-diamine Chemical compound N=1C=CNC=1CNCCN(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 WEZLIYLAGMXZGO-UHFFFAOYSA-N 0.000 description 1
CFZVQPIGMZCPFB-UHFFFAOYSA-N N-(1H-imidazol-2-ylmethyl)-N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-7-amine Chemical compound C=1C=C(CN(CC=2NC=CN=2)C2CC3=NC=CC=C3CC2)C=CC=1CNCC1=CC=CC=N1 CFZVQPIGMZCPFB-UHFFFAOYSA-N 0.000 description 1
HUQUYFJWQMETSC-UHFFFAOYSA-N N-(1H-imidazol-5-ylmethyl)-N'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-N'-(5,6,7,8-tetrahydroquinolin-8-yl)ethane-1,2-diamine Chemical compound C=1NC=NC=1CNCCN(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 HUQUYFJWQMETSC-UHFFFAOYSA-N 0.000 description 1
GVCLHOJGDIBACL-UHFFFAOYSA-N N-(2-methylpropyl)-N'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-N'-(5,6,7,8-tetrahydroquinolin-8-yl)ethane-1,2-diamine Chemical compound C1CCC2=CC=CN=C2C1N(CCNCC(C)C)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 GVCLHOJGDIBACL-UHFFFAOYSA-N 0.000 description 1
MXYQOQASCBNUDZ-UHFFFAOYSA-N N-(2-pyridin-2-ylethyl)-N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CNCC=2N=CC=CC=2)C=CC=1CN(C1C2=NC=CC=C2CCC1)CCC1=CC=CC=N1 MXYQOQASCBNUDZ-UHFFFAOYSA-N 0.000 description 1
VFVPTCKHUQJLLP-UHFFFAOYSA-N N-(3-phenylpropyl)-N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=CC=CC=1CCCN(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 VFVPTCKHUQJLLP-UHFFFAOYSA-N 0.000 description 1
LHDIGVATAPZAFK-UHFFFAOYSA-N N-(3H-imidazo[4,5-c]pyridin-2-ylmethyl)-N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CN(CC=2NC3=CC=NC=C3N=2)C2C3=NC=CC=C3CCC2)C=CC=1CNCC1=CC=CC=N1 LHDIGVATAPZAFK-UHFFFAOYSA-N 0.000 description 1
IIBURQNHZQCMKA-UHFFFAOYSA-N N-(furan-2-ylmethyl)-N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CN(CC=2OC=CC=2)C2C3=NC=CC=C3CCC2)C=CC=1CNCC1=CC=CC=N1 IIBURQNHZQCMKA-UHFFFAOYSA-N 0.000 description 1
IAKOZGHZGQFGTL-UHFFFAOYSA-N N-(naphthalen-2-ylmethyl)-N'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-N'-(5,6,7,8-tetrahydroquinolin-8-yl)ethane-1,2-diamine Chemical compound C=1C=C2C=CC=CC2=CC=1CNCCN(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 IAKOZGHZGQFGTL-UHFFFAOYSA-N 0.000 description 1
VXQJFGISVRSRNN-UHFFFAOYSA-N N-(naphthalen-2-ylmethyl)-N'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-N'-(5,6,7,8-tetrahydroquinolin-8-yl)propane-1,3-diamine Chemical compound C=1C=C2C=CC=CC2=CC=1CNCCCN(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 VXQJFGISVRSRNN-UHFFFAOYSA-N 0.000 description 1
CFESOCMLTKZTLO-UHFFFAOYSA-N N-(pyridin-2-ylmethyl)-1-[4-(4,7,10,17-tetrazabicyclo[11.3.1]heptadeca-1(17),13,15-trien-10-yl)phenyl]methanamine Chemical compound C=1C=C(N2CCC=3C=CC=C(N=3)CCNCCNCC2)C=CC=1CNCC1=CC=CC=N1 CFESOCMLTKZTLO-UHFFFAOYSA-N 0.000 description 1
DTLFISKHFHZEGV-UHFFFAOYSA-N N-(pyridin-2-ylmethyl)-N'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-N'-(5,6,7,8-tetrahydroquinolin-8-yl)ethane-1,2-diamine Chemical compound C=1C=CC=NC=1CNCCN(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 DTLFISKHFHZEGV-UHFFFAOYSA-N 0.000 description 1
UUAATDVFOQOPPY-UHFFFAOYSA-N N-(pyridin-2-ylmethyl)-N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C=1C=C(CN(CC=2N=CC=CC=2)C2C3=CC=CC=C3CCC2)C=CC=1CNCC1=CC=CC=N1 UUAATDVFOQOPPY-UHFFFAOYSA-N 0.000 description 1
WBIDRLRQDSWWJR-UHFFFAOYSA-N N-(pyridin-2-ylmethyl)-N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CN(CC=2N=CC=CC=2)C2C3=NC=CC=C3CCC2)C=CC=1CNCC1=CC=CC=N1 WBIDRLRQDSWWJR-UHFFFAOYSA-N 0.000 description 1
TWTLJZJKDUYSON-UHFFFAOYSA-N N-(pyridin-3-ylmethyl)-1-[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methanamine Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CNCC1=CC=CN=C1 TWTLJZJKDUYSON-UHFFFAOYSA-N 0.000 description 1
RTHCDPLDSUOFCC-UHFFFAOYSA-N N-(pyridin-4-ylmethyl)-1-[4-(1,4,8,11-tetrazacyclotetradec-1-ylmethyl)phenyl]methanamine Chemical compound C=1C=NC=CC=1CNCC(C=C1)=CC=C1CN1CCCNCCNCCCNCC1 RTHCDPLDSUOFCC-UHFFFAOYSA-N 0.000 description 1
HBQUSQLYWUYSNZ-UHFFFAOYSA-N N-[(3,5-dimethyl-2-phenyl-1,3-dihydropyrazol-4-yl)methyl]-N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound CC1N(C=2C=CC=CC=2)NC(C)=C1CN(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 HBQUSQLYWUYSNZ-UHFFFAOYSA-N 0.000 description 1
HVYYCEMREPWDCX-UHFFFAOYSA-N N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C=1C=C(CNC2C3=CC=CC=C3CCC2)C=CC=1CNCC1=CC=CC=N1 HVYYCEMREPWDCX-UHFFFAOYSA-N 0.000 description 1
UMQKDDXFDPRWKQ-UHFFFAOYSA-N N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-1,2,3,4-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CNC=2C=3NCCCC=3C=CC=2)C=CC=1CNCC1=CC=CC=N1 UMQKDDXFDPRWKQ-UHFFFAOYSA-N 0.000 description 1
BOSHJQMZFHOIEM-UHFFFAOYSA-N N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-5-amine Chemical compound C=1C=C(CNC2C3=CC=CN=C3CCC2)C=CC=1CNCC1=CC=CC=N1 BOSHJQMZFHOIEM-UHFFFAOYSA-N 0.000 description 1
OWQFWPLLANSQQV-UHFFFAOYSA-N N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-7-amine Chemical compound C=1C=C(CNC2CC3=NC=CC=C3CC2)C=CC=1CNCC1=CC=CC=N1 OWQFWPLLANSQQV-UHFFFAOYSA-N 0.000 description 1
NVQPVMGRKSAJCF-UHFFFAOYSA-N N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CNC2C3=NC=CC=C3CCC2)C=CC=1CNCC1=CC=CC=N1 NVQPVMGRKSAJCF-UHFFFAOYSA-N 0.000 description 1
GSCRMXPAVFDDAJ-UHFFFAOYSA-N N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine Chemical compound C=1C=C(CNC2C3=NC=CC=C3CC2)C=CC=1CNCC1=CC=CC=N1 GSCRMXPAVFDDAJ-UHFFFAOYSA-N 0.000 description 1
MQVBXWKLLOZAJE-UHFFFAOYSA-N N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-N-(1,3-thiazol-2-ylmethyl)-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CN(CC=2SC=CN=2)C2C3=NC=CC=C3CCC2)C=CC=1CNCC1=CC=CC=N1 MQVBXWKLLOZAJE-UHFFFAOYSA-N 0.000 description 1
RKEIPHNVBYPWQO-UHFFFAOYSA-N N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydroquinolin-8-yl)-1,3-benzoxazol-2-amine Chemical compound C=1C=C(CN(C2C3=NC=CC=C3CCC2)C=2OC3=CC=CC=C3N=2)C=CC=1CNCC1=CC=CC=N1 RKEIPHNVBYPWQO-UHFFFAOYSA-N 0.000 description 1
UWAKJWARIZWAPY-UHFFFAOYSA-N N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydroquinolin-8-yl)pyrazine-2-carboxamide Chemical compound C=1N=CC=NC=1C(=O)N(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 UWAKJWARIZWAPY-UHFFFAOYSA-N 0.000 description 1
KNFODAPPVSMDKV-UHFFFAOYSA-N N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-N-(5,6,7,8-tetrahydroquinolin-8-yl)pyridine-2-carboxamide Chemical compound C=1C=CC=NC=1C(=O)N(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 KNFODAPPVSMDKV-UHFFFAOYSA-N 0.000 description 1
SUXWTBAOYVYILW-UHFFFAOYSA-N N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-N-(thiophen-2-ylmethyl)-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CN(CC=2SC=CC=2)C2C3=NC=CC=C3CCC2)C=CC=1CNCC1=CC=CC=N1 SUXWTBAOYVYILW-UHFFFAOYSA-N 0.000 description 1
IKZCJMKAYGBAGH-AVJYQCBHSA-N N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-N-[[(2R)-pyrrolidin-2-yl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CN(C[C@@H]2NCCC2)C2C3=NC=CC=C3CCC2)C=CC=1CNCC1=CC=CC=N1 IKZCJMKAYGBAGH-AVJYQCBHSA-N 0.000 description 1
VKBJDOBPGVLLTB-UHFFFAOYSA-N N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]naphthalen-1-amine Chemical compound C=1C=C(CNC=2C3=CC=CC=C3C=CC=2)C=CC=1CNCC1=CC=CC=N1 VKBJDOBPGVLLTB-UHFFFAOYSA-N 0.000 description 1
DIRVCOZGHSWRJP-UHFFFAOYSA-N N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]quinolin-8-amine Chemical compound C=1C=C(CNC=2C3=NC=CC=C3C=CC=2)C=CC=1CNCC1=CC=CC=N1 DIRVCOZGHSWRJP-UHFFFAOYSA-N 0.000 description 1
WTTKTVHBIVMMDP-UHFFFAOYSA-N N-[[4-[[(5-phenyl-1H-imidazol-2-yl)methyl-(pyridin-2-ylmethyl)amino]methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C1CCC2=CC=CN=C2C1NCC(C=C1)=CC=C1CN(CC=1N=CC=CC=1)CC(NC=1)=NC=1C1=CC=CC=C1 WTTKTVHBIVMMDP-UHFFFAOYSA-N 0.000 description 1
VPHPNWIYBHWZEE-UHFFFAOYSA-N N-benzyl-N'-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-N'-(5,6,7,8-tetrahydroquinolin-8-yl)ethane-1,2-diamine Chemical compound C=1C=CC=CC=1CNCCN(C1C2=NC=CC=C2CCC1)CC(C=C1)=CC=C1CNCC1=CC=CC=N1 VPHPNWIYBHWZEE-UHFFFAOYSA-N 0.000 description 1
NJDVDIVVFUXOHL-UHFFFAOYSA-N N-benzyl-N-[[4-[(pyridin-2-ylmethylamino)methyl]phenyl]methyl]-5,6,7,8-tetrahydroquinolin-8-amine Chemical compound C=1C=C(CN(CC=2C=CC=CC=2)C2C3=NC=CC=C3CCC2)C=CC=1CNCC1=CC=CC=N1 NJDVDIVVFUXOHL-UHFFFAOYSA-N 0.000 description 1
102100007544 NCAM1 Human genes 0.000 description 1
101700077124 NCAM1 Proteins 0.000 description 1
102000003729 Neprilysin Human genes 0.000 description 1
206010072359 Neuromyotonia Diseases 0.000 description 1
206010029331 Neuropathy peripheral Diseases 0.000 description 1
OSTGTTZJOCZWJG-UHFFFAOYSA-N Nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
241000714209 Norwalk virus Species 0.000 description 1
241000283898 Ovis Species 0.000 description 1
240000007019 Oxalis corniculata Species 0.000 description 1
102000016387 Pancreatic Elastase Human genes 0.000 description 1
108010067372 Pancreatic Elastase Proteins 0.000 description 1
229960002340 Pentostatin Drugs 0.000 description 1
FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
102000005877 Peptide Initiation Factors Human genes 0.000 description 1
108010044843 Peptide Initiation Factors Proteins 0.000 description 1
241000709664 Picornaviridae Species 0.000 description 1
229960002169 Plerixafor Drugs 0.000 description 1
206010065159 Polychondritis Diseases 0.000 description 1
208000005987 Polymyositis Diseases 0.000 description 1
108050006987 Poxvirus Proteins 0.000 description 1
IYABWNGZIDDRAK-UHFFFAOYSA-N Propadiene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical class N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
210000003324 RBC Anatomy 0.000 description 1
206010037912 Raynaud's phenomenon Diseases 0.000 description 1
206010038294 Reiter's syndrome Diseases 0.000 description 1
102000009661 Repressor Proteins Human genes 0.000 description 1
108010034634 Repressor Proteins Proteins 0.000 description 1
241000712907 Retroviridae Species 0.000 description 1
206010072736 Rheumatic disease Diseases 0.000 description 1
206010039073 Rheumatoid arthritis Diseases 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N Rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
241000724205 Rice stripe tenuivirus Species 0.000 description 1
102100001435 SH2D1A Human genes 0.000 description 1
101710013575 SH2D1A Proteins 0.000 description 1
101700025758 SP01 Proteins 0.000 description 1
210000003296 Saliva Anatomy 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
241001468001 Salmonella virus SP6 Species 0.000 description 1
206010039580 Scar Diseases 0.000 description 1
206010039722 Scoliosis Diseases 0.000 description 1
241000287219 Serinus canaria Species 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
206010040767 Sjogren's syndrome Diseases 0.000 description 1
206010072610 Skeletal dysplasia Diseases 0.000 description 1
210000003491 Skin Anatomy 0.000 description 1
108020004459 Small Interfering RNA Proteins 0.000 description 1
229920001891 Small hairpin RNA Polymers 0.000 description 1
241000713675 Spumavirus Species 0.000 description 1
206010072148 Stiff person syndrome Diseases 0.000 description 1
208000003265 Stomatitis Diseases 0.000 description 1
229960001052 Streptozocin Drugs 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
210000004243 Sweat Anatomy 0.000 description 1
208000000389 T-Cell Leukemia Diseases 0.000 description 1
210000000662 T-Lymphocyte Subsets Anatomy 0.000 description 1
206010043207 Temporal arteritis Diseases 0.000 description 1
229960002180 Tetracycline Drugs 0.000 description 1
OFVLGDICTFRJMM-WESIUVDSSA-N Tetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O OFVLGDICTFRJMM-WESIUVDSSA-N 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
229960005454 Thioguanine Drugs 0.000 description 1
108010002487 Thomsen-Friedenreich antibodies Proteins 0.000 description 1
206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
102000036902 Thrombopoietin Human genes 0.000 description 1
108010041111 Thrombopoietin Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine Kinase Proteins 0.000 description 1
206010043778 Thyroiditis Diseases 0.000 description 1
235000015450 Tilia cordata Nutrition 0.000 description 1
235000011941 Tilia x europaea Nutrition 0.000 description 1
231100000765 Toxin Toxicity 0.000 description 1
229920001949 Transfer RNA Polymers 0.000 description 1
108020004566 Transfer RNA Proteins 0.000 description 1
206010068760 Ulcers Diseases 0.000 description 1
210000003954 Umbilical Cord Anatomy 0.000 description 1
230000036462 Unbound Effects 0.000 description 1
210000002444 Unipotent stem cell Anatomy 0.000 description 1
108020003635 Untranslated Regions Proteins 0.000 description 1
229920000146 Untranslated region Polymers 0.000 description 1
210000002700 Urine Anatomy 0.000 description 1
229940029983 VITAMINS Drugs 0.000 description 1
241000700618 Vaccinia virus Species 0.000 description 1
102000016350 Viral Proteins Human genes 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
206010047461 Viral infection Diseases 0.000 description 1
208000001756 Virus Disease Diseases 0.000 description 1
229940021016 Vitamin IV solution additives Drugs 0.000 description 1
201000001696 X-linked hyper IgM syndrome Diseases 0.000 description 1
NRAUADCLPJTGSF-ZPGVOIKOSA-N [(2R,3S,4R,5R,6R)-6-[[(3aS,7R,7aS)-7-hydroxy-4-oxo-1,3a,5,6,7,7a-hexahydroimidazo[4,5-c]pyridin-2-yl]amino]-5-[[(3S)-3,6-diaminohexanoyl]amino]-4-hydroxy-2-(hydroxymethyl)oxan-3-yl] carbamate Chemical compound NCCC[C@H](N)CC(=O)N[C@@H]1[C@@H](O)[C@H](OC(N)=O)[C@@H](CO)O[C@H]1\N=C/1N[C@H](C(=O)NC[C@H]2O)[C@@H]2N\1 NRAUADCLPJTGSF-ZPGVOIKOSA-N 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N acetylene Chemical compound C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000003044 adaptive Effects 0.000 description 1
238000007792 addition Methods 0.000 description 1
201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
231100000494 adverse effect Toxicity 0.000 description 1
229960000548 alemtuzumab Drugs 0.000 description 1
125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
150000008052 alkyl sulfonates Chemical class 0.000 description 1
239000002295 alkylating antineoplastic agent Substances 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
201000004384 alopecia Diseases 0.000 description 1
108010026331 alpha-Fetoproteins Proteins 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
230000000781 anti-lymphocytic Effects 0.000 description 1
230000000890 antigenic Effects 0.000 description 1
239000002246 antineoplastic agent Substances 0.000 description 1
238000002617 apheresis Methods 0.000 description 1
125000005418 aryl aryl group Chemical group 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
210000000270 basal cell Anatomy 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
JAPMJSVZDUYFKL-UHFFFAOYSA-N bicyclo[3.1.0]hexane Chemical compound C1CCC2CC21 JAPMJSVZDUYFKL-UHFFFAOYSA-N 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
235000010290 biphenyl Nutrition 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
239000012503 blood component Substances 0.000 description 1
238000009583 bone marrow aspiration Methods 0.000 description 1
210000002798 bone marrow cell Anatomy 0.000 description 1
210000000069 breast epithelial cell Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
125000005569 butenylene group Chemical group 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
229960005243 carmustine Drugs 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000002771 cell marker Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000002659 cell therapy Methods 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
229960001411 chlormethine Drugs 0.000 description 1
230000001684 chronic Effects 0.000 description 1
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
230000004087 circulation Effects 0.000 description 1
229960002436 cladribine Drugs 0.000 description 1
ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical group OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 description 1
230000001332 colony forming Effects 0.000 description 1
239000000306 component Substances 0.000 description 1
230000037011 constitutive activity Effects 0.000 description 1
201000003278 cryoglobulinemia Diseases 0.000 description 1
238000005138 cryopreservation Methods 0.000 description 1
101700067609 ctx Proteins 0.000 description 1
125000000392 cycloalkenyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000004976 cyclobutylene group Chemical group 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
JJWIOXUMXIOXQN-UHFFFAOYSA-N cyclohexadecane Chemical compound C1CCCCCCCCCCCCCCC1 JJWIOXUMXIOXQN-UHFFFAOYSA-N 0.000 description 1
125000004956 cyclohexylene group Chemical group 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000004979 cyclopentylene group Chemical group 0.000 description 1
125000004980 cyclopropylene group Chemical group 0.000 description 1
239000000409 cytokine receptor agonist Substances 0.000 description 1
230000001086 cytosolic Effects 0.000 description 1
230000001472 cytotoxic Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
239000002619 cytotoxin Substances 0.000 description 1
230000034994 death Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
239000000412 dendrimer Substances 0.000 description 1
229920000736 dendritic polymer Polymers 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
230000005670 electromagnetic radiation Effects 0.000 description 1
238000005421 electrostatic potential Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
201000009273 endometriosis Diseases 0.000 description 1
230000003511 endothelial Effects 0.000 description 1
210000002514 epidermal stem cell Anatomy 0.000 description 1
238000006345 epimerization reaction Methods 0.000 description 1
229940105423 erythropoietin Drugs 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
CKSJXOVLXUMMFF-UHFFFAOYSA-N exalamide Chemical compound CCCCCCOC1=CC=CC=C1C(N)=O CKSJXOVLXUMMFF-UHFFFAOYSA-N 0.000 description 1
230000001747 exhibiting Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000001605 fetal Effects 0.000 description 1
239000012530 fluid Substances 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
230000003325 follicular Effects 0.000 description 1
238000005755 formation reaction Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
238000001476 gene delivery Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000002068 genetic Effects 0.000 description 1
201000002406 genetic disease Diseases 0.000 description 1
102000018146 globin family Human genes 0.000 description 1
108060003196 globin family Proteins 0.000 description 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
239000001963 growth media Substances 0.000 description 1
201000005787 hematologic cancer Diseases 0.000 description 1
150000002373 hemiacetals Chemical class 0.000 description 1
210000003897 hepatic stem cell Anatomy 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
125000004475 heteroaralkyl group Chemical group 0.000 description 1
125000006038 hexenyl group Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000005980 hexynyl group Chemical group 0.000 description 1
230000003284 homeostatic Effects 0.000 description 1
230000013632 homeostatic process Effects 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
201000009794 idiopathic pulmonary fibrosis Diseases 0.000 description 1
230000001861 immunosuppresant Effects 0.000 description 1
239000002596 immunotoxin Substances 0.000 description 1
230000002637 immunotoxin Effects 0.000 description 1
230000001976 improved Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002757 inflammatory Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000000968 intestinal Effects 0.000 description 1
230000003834 intracellular Effects 0.000 description 1
239000011630 iodine Substances 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
125000005990 isobenzothienyl group Chemical group 0.000 description 1
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000005956 isoquinolyl group Chemical group 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
230000002147 killing Effects 0.000 description 1
239000004571 lime Substances 0.000 description 1
238000011068 load Methods 0.000 description 1
229960002247 lomustine Drugs 0.000 description 1
201000003265 lymphadenitis Diseases 0.000 description 1
201000001268 lymphoproliferative syndrome Diseases 0.000 description 1
239000006249 magnetic particle Substances 0.000 description 1
239000006148 magnetic separator Substances 0.000 description 1
201000005505 measles Diseases 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229960001428 mercaptopurine Drugs 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 1
229920001239 microRNA Polymers 0.000 description 1
239000002679 microRNA Substances 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
230000003278 mimic Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
201000010770 muscular disease Diseases 0.000 description 1
230000036473 myasthenia Effects 0.000 description 1
230000002107 myocardial Effects 0.000 description 1
201000009623 myopathy Diseases 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
201000001119 neuropathy Diseases 0.000 description 1
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
229940015758 omidubicel Drugs 0.000 description 1
210000000963 osteoblast Anatomy 0.000 description 1
230000000790 osteoblast Effects 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
125000004043 oxo group Chemical group O=* 0.000 description 1
125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
230000005298 paramagnetic Effects 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
125000005981 pentynyl group Chemical group 0.000 description 1
239000012466 permeate Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
210000001778 pluripotent stem cell Anatomy 0.000 description 1
125000003367 polycyclic group Chemical group 0.000 description 1
239000011148 porous material Substances 0.000 description 1
201000002728 primary biliary cirrhosis Diseases 0.000 description 1
201000002367 primary immunodeficiency disease Diseases 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
125000006410 propenylene group Chemical group 0.000 description 1
BVUGBCYESKXQKQ-UHFFFAOYSA-N propoxycyclohexatriene Chemical group CCCOC1=CC=C=C[CH]1 BVUGBCYESKXQKQ-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
230000001681 protective Effects 0.000 description 1
YZCKVEUIGOORGS-IGMARMGPSA-N protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
201000004681 psoriasis Diseases 0.000 description 1
125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000000552 rheumatic Effects 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
201000000306 sarcoidosis Diseases 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000037387 scars Effects 0.000 description 1
239000002924 silencing RNA Substances 0.000 description 1
239000004055 small Interfering RNA Substances 0.000 description 1
241000894007 species Species 0.000 description 1
201000002661 spondylitis Diseases 0.000 description 1
238000005556 structure-activity relationship Methods 0.000 description 1
125000005017 substituted alkenyl group Chemical group 0.000 description 1
125000004426 substituted alkynyl group Chemical group 0.000 description 1
125000005717 substituted cycloalkylene group Chemical group 0.000 description 1
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
150000007970 thio esters Chemical class 0.000 description 1
230000001256 tonic Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
230000001052 transient Effects 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
201000006704 ulcerative colitis Diseases 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229930003231 vitamins Natural products 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1

JP2021522019A 2018-10-31 2019-10-31 造血幹・前駆細胞移植療法の方法 Pending JP2022505615A (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US201862753865P	2018-10-31	2018-10-31
US62/753,865		2018-10-31
US201962860866P	2019-06-13	2019-06-13
US62/860,866		2019-06-13
PCT/US2019/059039 WO2020092694A2 (en)	2018-10-31	2019-10-31	Methods for hematopoietic stem and progenitor cell transplant therapy

Publications (2)

Publication Number	Publication Date
JP2022505615A JP2022505615A (ja)	2022-01-14
JPWO2020092694A5 true JPWO2020092694A5 (zh)	2022-11-09

Family

ID=70464231

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2021522019A Pending JP2022505615A (ja)	2018-10-31	2019-10-31	造血幹・前駆細胞移植療法の方法

Country Status (7)

Country	Link
US (1)	US20210379113A1 (zh)
EP (1)	EP3874027A4 (zh)
JP (1)	JP2022505615A (zh)
CN (1)	CN113302287A (zh)
AU (1)	AU2019374064A1 (zh)
CA (1)	CA3117685A1 (zh)
WO (1)	WO2020092694A2 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20230165958A1 (en) *	2020-04-27	2023-06-01	Children's Hospital Medical Center	Precision Dosing Regimen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6544787B1 (en) *	1996-11-15	2003-04-08	Hadash Medical Research Services And Development Ltd.	Non-myeloablative/lymphoablative conditioning regimen to induce patient anti-donor unresponsiveness in stem cell transplantation
WO1999025367A2 (en) *	1997-11-14	1999-05-27	The General Hospital Corporation	Treatment of hematologic disorders
PE20100362A1 (es) *	2008-10-30	2010-05-27	Irm Llc	Derivados de purina que expanden las celulas madre hematopoyeticas
WO2018136606A1 (en) *	2017-01-18	2018-07-26	Thalia Papayannopoulou	Compositions and methods for transplant recipient conditioning

2019
- 2019-10-31 JP JP2021522019A patent/JP2022505615A/ja active Pending
- 2019-10-31 CA CA3117685A patent/CA3117685A1/en active Pending
- 2019-10-31 WO PCT/US2019/059039 patent/WO2020092694A2/en unknown
- 2019-10-31 AU AU2019374064A patent/AU2019374064A1/en not_active Abandoned
- 2019-10-31 EP EP19879239.2A patent/EP3874027A4/en not_active Withdrawn
- 2019-10-31 CN CN201980085571.0A patent/CN113302287A/zh active Pending
- 2019-10-31 US US17/290,537 patent/US20210379113A1/en active Pending

Publication	Publication Date	Title
US10058573B1 (en)	2018-08-28	Dosing regimens for the mobilization of hematopoietic stem cells
JP7412341B2 (ja)	2024-01-12	造血幹細胞および前駆細胞の増幅のための組成物および方法
JP2024023226A (ja)	2024-02-21	造血幹細胞及び前駆細胞を動員させるための投薬レジメン
US20220096559A1 (en)	2022-03-31	Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
JP2021503008A (ja)	2021-02-04	造血幹細胞および前駆細胞移植療法のための組成物および方法
US11260079B2 (en)	2022-03-01	Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
JP2022505615A (ja)	2022-01-14	造血幹・前駆細胞移植療法の方法
EP3735412B1 (en)	2024-02-21	Compositions and methods for the expansion of hematopoietic stem and progenitor cells and treatment of inherited metabolic disorders
US20220401481A1 (en)	2022-12-22	Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
JPWO2020092694A5 (zh)	2022-11-09
US20230414565A1 (en)	2023-12-28	Compositions and methods for treating hematological malignancies
US20240189387A1 (en)	2024-06-13	Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients
CN115997009A (zh)	2023-04-21	用于在体内转导造血干细胞和祖细胞的方法和组合物